ANI Pharmaceuticals Announces $560 Million Acquisition of Egetis Therapeutics
ANI Pharmaceuticals (ANIP) has entered into an agreement to acquire Swedish biotechnology firm Egetis Therapeutics (PDPHF) in a deal valued at approximately $560 million. The acquisition is a strategic move designed to accelerate ANI's transition toward a product portfolio heavily focused on rare diseases. By integrating Egetis’ assets, ANI aims to meet its long-term corporate objective of deriving a significant portion of its total revenue from the rare disease sector by the end of 2030. The deal is expected to bolster ANI's pipeline and expand its footprint in specialized therapeutic markets.
Tickers: $ANIP
Topics: Acquisition Biotechnology Rare Disease